Trial Profile
SPINOZA. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms SPINOZA
- 06 Oct 2016 Status changed from active, no longer recruiting to discontinued due to wthdrawal of sponsor support.
- 05 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2015 New trial record